Eligible patients pay as little as $0 for their prescription with copay assistance, automatically applied when a prescription is sent to an in-network specialty pharmacy*
Eligible patients pay as little as $0 for their prescription with copay assistance, automatically applied when a prescription is sent to an in-network specialty pharmacy*
Two easy ways for eligible patients to get started with Arna Assist:

Fill out the Service Request Form and bring it to your next doctor’s appointment, a Arna Assist Specialist will contact you directly to complete your enrollment.
*Co-Pay Assistance Program Eligibility and Details:
Restrictions apply. Patients receiving Medicare, Medicaid, or that are participating in any other state or federally subsidized pharmacy benefit program are not eligible for the BRONCHITOL Patient Assistance Program but may be eligible for other non-financial components of the program. Please see full Terms and Conditions for additional eligibility requirements.
BRONCHITOL is contraindicated in patients with hypersensitivity to mannitol or to any of the capsule components. BRONCHITOL is contraindicated in patients who fail to pass the BRONCHITOL Tolerance Test (BTT).
BRONCHITOL can cause bronchospasm, which can be severe in susceptible patients. Because of the risk of bronchospasm, prior to prescribing BRONCHITOL, patients must pass the BRONCHITOL Tolerance Test (BTT). The BTT must be administered under the supervision of a healthcare practitioner who can treat severe bronchospasm.
Patients who pass the BRONCHITOL tolerance test (BTT) may experience bronchospasm with add-on maintenance therapy with BRONCHITOL. Patients should premedicate with an inhaled short-acting bronchodilator prior to each administration of BRONCHITOL. If bronchospasm occurs, immediately discontinue BRONCHITOL and treat bronchospasm with an inhaled short-acting bronchodilator.
Hemoptysis can occur with BRONCHITOL use. Monitor patients with history of episodes of hemoptysis. If hemoptysis occurs, discontinue use of BRONCHITOL.
Most common adverse reactions (≥3%) include cough, hemoptysis, oropharyngeal pain, vomiting, bacteria sputum identified, pyrexia, and arthralgia.
BRONCHITOL is a prescription medicine that is used along with other therapies to improve lung function in people 18 years of age and older with cystic fibrosis (CF).
BRONCHITOL is only for adults who have passed the BRONCHITOL Tolerance Test (BTT). Your first dose of BRONCHITOL is given during the BTT by your healthcare provider and tests if BRONCHITOL is right for you. Your healthcare provider will use equipment to monitor you and have medicine ready if you have bronchospasm during the test. If you have bronchospasm during your BTT, then you should not be prescribed BRONCHITOL.
BRONCHITOL should not be used in children and adolescents. It is not known if BRONCHITOL is safe and effective in children under 18 years of age.